BR96 Bearing

This is a phase II trial comparing delivery of the agent doxorubicin either as an immunoconjugate linked to the monoclonal anti-Lewis antibody BR96 or

BR96 sFv- PE40 AND BR96 sFv

br96 We have constructed a single-chain immunotoxin composed of the carcinoma-reactive antibody BR96 and a truncated form of Pseudomonas exotoxin The chimeric

br96 lottery result We have constructed a single-chain immunotoxin composed of the carcinoma-reactive antibody BR96 and a truncated form of Pseudomonas exotoxin The chimeric